Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review

Jie Wang, Yigen Shen, Jiaoni Wang, Yangjing Xue, Lianming Liao, Saroj Thapa and Kangting Ji _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:46461-46467. https://doi.org/10.18632/oncotarget.17518

Metrics: PDF 2277 views  |   HTML 2627 views  |   ?  


Jie Wang1,*, Yigen Shen1,*, Jiaoni Wang1, Yangjing Xue1, Lianming Liao2, Saroj Thapa1 and Kangting Ji1

1Department of Cardiology, The Second Affiliated and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou 325000, Zhejiang, China

2Department of Oncology, Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 3250112, Fujian, China

*These authors have contributed equally to this work

Correspondence to:

Kangting Ji, email: [email protected]

Keywords: phosphodiesterase type 5 inhibitors, malignant melanoma, basal cell carcinoma, meta-analysis, systematic review

Received: December 10, 2016     Accepted: April 04, 2017     Published: April 29, 2017


Data on the association between using PDE5 inhibitors and malignant melanoma are conflicting. To estimate the relation of using PDE5 inhibitors with risk of malignant melanoma, Medline (Ovid) and Embase (Ovid) databases were searched up to February 2017, and a random effects model was used to calculate the summary risk estimates. Five observational studies were included. Five studies reports encompassed a total of 15,979 melanoma cases occurring among 1, 188,414 participants. The pooled multivariable-adjusted RR of melanoma in patients with using PDE5 inhibitors was 1.12 (95% CI: 1.03–1.21, I2 = 0.48). Findings from this systematic review support that PDE5 inhibitor use is associated with increased risk of melanoma in ED patients, the result remains inclusive and warrants further study in the future.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17518